We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Advances But Underperforms Market: Key Facts
Read MoreHide Full Article
Medpace (MEDP - Free Report) ended the recent trading session at $395.95, demonstrating a +0.52% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.77%. Meanwhile, the Dow gained 0.49%, and the Nasdaq, a tech-heavy index, added 0.95%.
Heading into today, shares of the provider of outsourced clinical development services had gained 0.16% over the past month, lagging the Medical sector's gain of 1.49% and the S&P 500's gain of 3.71% in that time.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is expected to report EPS of $2.52, up 30.57% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $529.73 million, up 14.94% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $11.29 per share and a revenue of $2.17 billion, representing changes of +27.14% and +14.92%, respectively, from the prior year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Right now, Medpace possesses a Zacks Rank of #2 (Buy).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 34.91. Its industry sports an average Forward P/E of 18.95, so one might conclude that Medpace is trading at a premium comparatively.
It's also important to note that MEDP currently trades at a PEG ratio of 1.95. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical Services industry stood at 1.49 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 97, this industry ranks in the top 39% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medpace (MEDP) Advances But Underperforms Market: Key Facts
Medpace (MEDP - Free Report) ended the recent trading session at $395.95, demonstrating a +0.52% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.77%. Meanwhile, the Dow gained 0.49%, and the Nasdaq, a tech-heavy index, added 0.95%.
Heading into today, shares of the provider of outsourced clinical development services had gained 0.16% over the past month, lagging the Medical sector's gain of 1.49% and the S&P 500's gain of 3.71% in that time.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is expected to report EPS of $2.52, up 30.57% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $529.73 million, up 14.94% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $11.29 per share and a revenue of $2.17 billion, representing changes of +27.14% and +14.92%, respectively, from the prior year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Right now, Medpace possesses a Zacks Rank of #2 (Buy).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 34.91. Its industry sports an average Forward P/E of 18.95, so one might conclude that Medpace is trading at a premium comparatively.
It's also important to note that MEDP currently trades at a PEG ratio of 1.95. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical Services industry stood at 1.49 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 97, this industry ranks in the top 39% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.